A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus
Withdrawn before enrolling · Phase 1
Conditions studied: Lupus Nephritis, Systemic Lupus Erythematosus
In brief
The purpose of the study is to evaluate the safety and preliminary efficacy of ATA3219 for treatment of participants with lupus nephritis (LN) following lymphodepletion (LD) and in participants with extrarenal systemic lupus erythematosus (SLE) without LD.
Key facts
- Study ID
- NCT06429800
- Run by
- Atara Biotherapeutics
- People needed
- 0
- Starts
- 2025-04-16
- Expected to finish
- 2025-04-16
- Last updated by the study team
- 2025-04-24
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Atara Biotherapeutics — Thousand Oaks, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.